Literature DB >> 9365544

Evaluation of the tetracycline-repressible transactivator system for inducible gene expression in human prostate cancer cell lines.

J E Gschwend1, W R Fair, C T Powell.   

Abstract

BACKGROUND: Studies of genes that may inhibit growth or induce death of cells are facilitated greatly by tightly controlled expression of those genes. A promising system for control of transgene expression over a wide range is the tetracycline-repressible transactivator (tTA) system developed by Gossen and Bujard [Proc Natl Acad Sci USA 1992;89:5547-5551]. We investigated the effectiveness of this system in three well-established human prostate cancer cell lines.
METHODS: LNCaP, PC-3, and Tsu-Pr1 cells were transfected with a vector coding for the tTA protein and/or a luciferase reporter vector, and luciferase activity was measured in the presence and absence of tetracycline or the tTA protein.
RESULTS: In the absence of tetracycline, the tTA system yielded high levels of luciferase activity in all three cell lines. Background luciferase activity in the presence of tetracycline was nearly undetectable in LNCaP cells, moderate in Tsu-Pr1 cells, and more than 20-fold higher in PC-3 than in Tsu-Pr1 cells. Similar background activity was observed in Tsu-Pr1 and PC-3 cells, even in the absence of the transactivator protein.
CONCLUSIONS: The tTA system should be useful for stable transfection of cytotoxic transgenes in LNCaP cells and for control of transgene expression over a wide range in Tsu-Pr1 and PC-3 cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365544     DOI: 10.1002/(sici)1097-0045(19971101)33:3<166::aid-pros4>3.0.co;2-h

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  1 in total

1.  Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.

Authors:  Evan R Zynda; Vitaliy Matveev; Michael Makhanov; Alexander Chenchik; Eugene S Kandel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.